As endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030, predicts Roots Analysis

So far, more than 100 different cannabinoids have been identified, and there is a growing body of evidence supporting the clinical benefits of this class of compounds in treating the symptoms of a wide variety of chronic health conditions

Roots Analysis is pleased to announce the publication of its recent study, titled, “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“

• More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over180 cannabinoid-derivatives that target the human endocannabinoid signaling system
• The pipeline features a variety of marketed / clinical stage therapies, being investigated for a wide range of target disease indications and designed for administration via different routes
• The geographical landscape of this industry is likely to evolve in the next few years as federal authorities legalize the use of medical cannabis across multiple countries
• Despite the associated stigma, many organizations have extended financial support to aid research efforts in this domain; the focus is on understanding the clinical benefits of endocannabinoid signaling in different diseases
• The growing interest in this field is also reflected by the 170+ partnerships that have been signed in the last five years, involving both international and indigenous stakeholders, across different geographical marketplaces

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

• A detailed assessment of the current market landscape of drug developers engaged in the development of endocannabinoid system targeted therapeutics.
• Detailed profiles of developers of endocannabinoid system targeted therapeutics (shortlisted on the basis of the number of development programs).
• An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted therapeutics projects.
• An analysis of the partnerships that have been established in this domain, in the recent past.
• A detailed analysis of the various mergers and acquisitions that have taken place in this domain, between 2016-2020
• An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers in the domain of endocannabinoid system targeted therapeutics.
• A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
• Target Disease Indication
• Cancer
• Genetic Disorders
• Neurological Indications
• Others
• Route of Administration
• Oral
• Inhalation
• Key Geographies
• North America
• Europe
• Asia-Pacific and the Rest of the World

Key companies covered in the report

• GW Pharmaceuticals
• Corbus Pharmaceuticals
• Tilray
• Tetra Bio-Pharma
• Botanix Pharmaceuticals
• Kalytera Therapeutics
• Therapix Biosciences
• Echo Pharmaceuticals
• Avicanna
• GB Sciences

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

Other Recent Offerings

1. Neoantigen Targeted Therapies Market, 2019-2030
2. Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics
3. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030

Contact:
Gaurav Chaudhary
+1 (415) 800 3415

+44 (122) 391 1091
[email protected]